Remarkably, we observed that high DVL2 expression was significantly associated with both poor OS and DMFS with a hazard ratio of 1.87 and 2.12 (p < 0.0001) in 276 HER2-amplified breast cancer patient cohort (Fig. 1D) indicating potential prognostic role of DVL2 in HER2+ breast cancer patients. Here, ERBB2 is linked to breast cancer.